Like the first death reported in March, Sarepta Therapeutics attributed the fatality to a case of acute liver failure following dosing of the Duchenne muscular dystrophy gene therapy, Elevidys. The company has proposed an immunosuppressive regimen to mitigate the liver injury risk posed by the therapy.
The post Sarepta Stops Stop Shipments of Muscular Dystrophy Gene Therapy After Second Patient Death appeared first on MedCity News.
